<DOC>
	<DOCNO>NCT00972959</DOCNO>
	<brief_summary>The aim study evaluate effect bortezomib combination dexamethasone zoledronic acid bone mineral density ( BMD ) skeletal related event ( SREs ) Patients Multiple Myeloma Have Relapsed 1-3 Prior Lines Therapy</brief_summary>
	<brief_title>Effect Combination Bortezomib/Dexamethasone/Zoledronic Acid Bone Disease Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines Therapy</brief_title>
	<detailed_description>Multiple Myeloma represent malignant proliferation plasma cell derive single clone . The common symptom myeloma , affect 70 % patient diagnosis , bone pain . The pain usually involve back rib , precipitate movement . Bone fracture commonly see myeloma patient may present persistent localize pain . VELCADE ( bortezomib ) proteasome inhibitor use treatment multiple myeloma . VELCADE seem first agent combine significant anti-myeloma activity beneficial effect bone remodel . Thus , appear promising tool treatment myeloma patient . In study , regimen consist bortezomib/dexamethasone/zoledronic acid use . The rationale use regimen : - VELCADE ( bortezomib ) indicate treatment relapse myeloma patient participate study also beneficial effect biochemical marker bone formation . - In phase II study , addition dexamethasone patient suboptimal response bortezomib alone improve efficacy relapse refractory multiple myeloma patient , without increase adverse event . Therefore , study , addition dexamethasone aim provide optimal therapy participate myeloma patient . - Zoledronic acid , potent i.v . bisphosphonate , use establish effect reduce skeletal related event patient multiple myeloma due inhibitory effect osteoclastic bone resorption . Dosages time dosage base current recommendation guideline treatment myeloma patient Have Relapsed 1-3 Prior Lines Therapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients Multiple Myeloma Have Relapsed 13 Prior Lines Therapy Women &gt; 50 year old Κarnofsky performance status ≥ 60 ( patient low performance status due myeloma bone disease also include ) Measurable disease Platelet count &gt; 50x10 ( 9 ) /L Neutrophil count &gt; 0.75x10 ( 9 ) /L Hemoglobin ≥7.0 g/dL ( use recombinant human erythropoietin red blood Hell transfusion maintain hemoglobin level 7.0 g/dL exclusion criterion ) Serum ALT AST ≤ 3fold upper normal limit Serum bilirubin ≤ 2fold upper normal limit Serum Calcium ≤ 10.5 mg/dL Expected survival ≥ 2 month Signed informed consent Presence another cancer Serious medical psychiatric illness likely interfere participation clinical study Grade 24 peripheral neuropathy neuropathic pain Grade 2 high define NCI CTCAE version 3 Pregnant woman &gt; 50 year old breastfeed Woman &gt; 50 year old capable become pregnant [ anyone undergone hysterectomy , ovary remove postmenopausal 24 month row use adequate contraception Known suspect hypersensitivity intolerance bortezomib , boron , mannitol , zoledronic acid , dexamethasone , heparin ( indwell catheter use ) Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month prior first dose study drug ) Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrolment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 4 , NYHA Classification Cardiac Disease ) , uncontrolled angina , pericardial disease , cardiac amyloidosis Acute diffuse infiltrative pulmonary disease History hypotension patient decrease blood pressure ( sit systolic blood pressure [ SBP ] 100 mmHg and/or sit diastolic blood pressure [ DBP ] 60 mmHg ) Patient receive extensive radiation therapy , systemic chemotherapy , antineoplastic therapy within 4 week prior enrolment Patient receive drug agent inhibit ( e.g. , cimetidine , erythromycin , fluoxetine , ketoconazole , paroxetine ) induce ( e.g. , carbamazepine , glucocorticoid , phenobarbital , rifampin ) CYP2C19 CYP3A4 within 14 day first dose VELCADE ( proton pump inhibitor allow ) Need therapy concomitant CYP 3A4 inhibitor ( e.g. , itraconazole , fluconazole , clarithromycin , erythromycin , norfloxacin , fluvoxamine , cimetidine , indinavir , ritonavir ) inducer ( e.g. , efavirenz , barbiturate , phenytoin , rifampin , glitazones ) . Proton pump inhibitor allow . Patient receive experimental drug use experimental medical device within 4 week prior plan start treatment . Concurrent participation nontreatment study allow , provide interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>1-3 Prior Lines Therapy</keyword>
	<keyword>bortezomib ( Velcade )</keyword>
	<keyword>zoledronic acid ( Zometa )</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone pain</keyword>
	<keyword>bone metabolism</keyword>
	<keyword>osteolytic lesion</keyword>
	<keyword>DEXA-scans</keyword>
	<keyword>X-ray radiography</keyword>
</DOC>